Share-based Payment Arrangement, Expense in USD of IN8BIO, INC. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
In8 Bio, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q1 2020 to Q3 2025.
  • In8 Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $692K, a 60.8% decline year-over-year.
  • In8 Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $3.3M, a 39.1% decline year-over-year.
  • In8 Bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5M, a 14.4% increase from 2023.
  • In8 Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4.37M, a 26% increase from 2022.
  • In8 Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.47M, a 58% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

IN8BIO, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $3.3M $692K -$1.07M -60.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $4.38M $955K -$216K -18.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $4.59M $831K -$409K -33% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 $5M $825K -$427K -34.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 $5.43M $1.76M +$524K +42.3% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $4.9M $1.17M +$152K +14.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $4.75M $1.24M +$381K +44.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $4.37M $1.25M +$330K +35.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 $4.04M $1.24M +$343K +38.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $3.7M $1.02M +$135K +15.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 $3.56M $859K +$95K +12.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 $3.47M $922K -$43K -4.46% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $3.51M $897K +$420K +88.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $3.09M $884K +$492K +126% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 $2.6M $764K +$403K +112% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 $2.2M $965K +$662K +218% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 $1.53M $477K +$461K +2881% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $1.07M $392K +$372K +1860% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 $700K $361K +$343K +1906% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 $357K $303K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 $16K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $20K Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 $18K Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10

IN8BIO, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $5M +$630K +14.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 $4.37M +$903K +26% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 $3.47M +$1.27M +58% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $2.2M +$1.84M +515% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $357K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.